Repligen to acquire BioLife Solutions for $1.5 billion as BeOne announces $300 million US expansion

Repligen announced it will acquire cell‑processing services provider BioLife Solutions in a transaction valued at roughly $1.5 billion. The deal adds BioLife’s platform to Repligen’s portfolio of bioprocessing tools.

Separately, contract manufacturing firm BeOne disclosed a $300 million investment to expand its operations in the United States, signaling confidence in domestic demand for biologics manufacturing capacity.

The announcement came alongside brief mentions of other industry players, including Lonza, Bachem and Samsung Biologics, though no further details were provided.